Welcome to #CancerX's inaugural steering committee! This group, alongside our 125+ member orgs, will execute our priorities w/in an ambitious timeframe-b/c #cancer waits for no one. bit.ly/3sGFfjP
Moonshots are the strategic pursuit of audacious goals through focus, resource prioritization, & #collaboration w/ all change agents. After meeting w/ @WhiteHouse & broader #CancerMoonshot community, we are thrilled to share our new strategic priorities bit.ly/460XYFo
A very successful meeting at The White House on Friday! Working w/ gov officials, federal reps, and other #CancerMoonshot initiatives, we will fuel the use of #digitalinnovation in the #oncology field. Sign up to learn more in the days ahead bit.ly/3BUdO7F
CancerX retweeted
Did you know we joined @CancerXMoonshot as a founding member? Our commitment to saving families from cancer fuels our interest through cancer risk prevention and early detections.
itnonline.com/content/volpar…
CancerX retweeted
Last week, we shared that Empatica is one of the founding members of #CancerX, whose mission is to drive innovation and create a future that is free from cancer.
Read our blog to find out more: empatica.com/blog/empatica-j…
@MoffittNews @_DiMeSociety @ONC_HealthIT @CancerXMoonshot
CancerX retweeted
While at #ASCO23, Dr. @PatrickHwuMD joined Santosh Mohan to discuss @CancerXMoonshot, a public-private partnership co-hosed by Moffitt Cancer Center to boost innovation in the fight against cancer.
Santosh Mohan Discusses CancerX at ASCO 2023
CancerX retweeted
Medable is proud to join @CancerXMoonshot as a founding member. Together, this group will foster a large community of patients, advocates, researchers, and clinicians who look to halve the cancer death rate within 25 years. Learn more: medable.com/knowledge-center…
CancerX retweeted
We are so thrilled to announce that the Canadian Cancer Society has joined as a founding member of @CancerXMoonshot.
🌟Exciting news! Introducing exceptional founding members joining us to shape #CancerX priorities and harness digital innovation for #CancerMoonshot goals. Be a part of our community of visionaries: cancerx.health @MoffittNews @_DiMeSociety
CancerX retweeted
Breaking News! @Volpara (ASX: VHT) is proud to be a founding member of @CancerXMoonshot, a groundbreaking public-private partnership dedicated to transforming cancer innovation in the United States.
@MoffittNews @_DiMeSociety @ONC_HealthIT
@HHS_Health
volparahealth.com/news/volpa…
CancerX retweeted
🎉 We are excited to share that Empatica is one of the founding members of #CancerX.
We’re proud to be joining this project, working with partners to help transform the lives of millions.
#CancerMoonshot
@MoffittNews @_DiMeSociety @ONC_HealthIT @CancerXMoonshot
🌟Exciting news! Introducing exceptional founding members joining us to shape #CancerX priorities and harness digital innovation for #CancerMoonshot goals. Be a part of our community of visionaries: cancerx.health @MoffittNews @_DiMeSociety
CancerX retweeted
👏 Welcome to the founding members of CancerX Moonshot! 🚀
🌟Exciting news! Introducing exceptional founding members joining us to shape #CancerX priorities and harness digital innovation for #CancerMoonshot goals. Be a part of our community of visionaries: cancerx.health @MoffittNews @_DiMeSociety
CancerX retweeted
🎉 Carium is thrilled to announce that we have joined the @CancerXMoonshot as a founding member, co-hosted by the @MoffittNews & @_DiMeSociety.
Together, we're on a mission to revolutionize cancer treatment and prevention.
go.carium.com/post/carium-jo…
#ASCO2023
Join us today at #ASCO23! Stop by the @MoffittNews booth #5029 from 2:30 PM to 5:00 PM CT to meet to our team in person and learn more about our ongoing #CancerX activities. Look out for @StephenKonya, @smitpats, Nik Pooviah, and @santoshSmohan
@ONC_HealthIT @_DiMeSociety
🌟Exciting news! Introducing exceptional founding members joining us to shape #CancerX priorities and harness digital innovation for #CancerMoonshot goals. Be a part of our community of visionaries: cancerx.health @MoffittNews @_DiMeSociety

















